Osteoarthritis Hip Outcomes

At Cell-Innovations all doctors and hospitals that use our technology continually track the outcomes from patients and have all shown excellent outcomes for their patients. Patients with osteoarthritis of the hips have demonstrated a 65% improvement on average in their osteoarthritis scores after treatment from in-house studies.

Not all patients will respond to Stromal Vascular Fraction (StroMed) cell treatment, with results indicating that approximately 90% of osteoarthritis patients will be responders and 10% will be non-responders to the treatment.

Importantly Cell-Innovations now has a simple proprietary test to indicate whether the patient will likely to respond to StroMed treatment, saving the patient undergoing the liposuction procedure and fees for treatment.

NB: The data presented below is a compilation of patient outcomes from in-house studies following StroMed treatment.

In 20 hip osteoarthritis patients at 1 year post-StroMed treatment there is an average improvement of 65%